Delivering drug discovery via our unique display technology
Peptide
Discovery
Peptide Display
What we do
Orbit Discovery offer services for the identification of peptide for radionuclide targeting, nucleic acid targeting, targeted protein degraders and for GPCR agonists. Using a combination of bead based technologies and microfluidics we perform high throughput screening encompassing large chemical space. The services can be configured for affinity screening (targeting binders), and also direct functional screens (in particular for agonists) using internally designed reporter cell lines.
Orbits mission is to offer our Partners solutions to identify peptide therapeutic hits by adopting high throughput affinity and functional screening.
Peptides for radiopharmaceutical delivery
Discovery of peptides for targeted peptides to specific tissues. Screening for specificity and cell surface binding with internalisation assays as required.
Nucleic acid delivery
Service for the discovery of peptides that target specific cell types with high content imaging to validate peptide internalisation
Soluble protein targeting peptides
Identification of peptides that specifically bind a target of interest with real time FACS analysis during the screening process. Ideal for finding peptides associated with PROTACS or molecular glues in targeted protein degraders.
Functional screening and peptide agonists
Using a combination of microfluidics and expertise in cell line development and assay development; FACS; high content imaging; and microfluidics, the Orbit platform can distinguish a functional response from single cells
Establishing a new standard
Orbit works with both industry and academic Partners to identify hits for existing and novel drug targets where therapeutic peptides can establish a new standard of care. Our expertise and services addresses targeting peptides (as part of a peptide conjugate), and functional screening for peptide agonists.
Find out how Orbit can help you with peptide discovery
